Comment
doi: 10.1056/NEJMc1808567.
Pembrolizumab plus Chemotherapy in Lung Cancer
Affiliations
- PMID: 30207917
- DOI: 10.1056/NEJMc1808567
Item in Clipboard
Comment
Pembrolizumab plus Chemotherapy in Lung Cancer
N Engl J Med.
.
No abstract available
Comment on
-
Pembrolizumab plus Chemotherapy in Lung Cancer.N Engl J Med. 2018 Sep 13;379(11):e18. doi: 10.1056/NEJMc1808567. N Engl J Med. 2018. PMID: 30211498 No abstract available.
-
Pembrolizumab plus Chemotherapy in Lung Cancer.N Engl J Med. 2018 Sep 13;379(11):e18. doi: 10.1056/NEJMc1808567. N Engl J Med. 2018. PMID: 30211499 No abstract available.
-
Pembrolizumab plus Chemotherapy in Lung Cancer.N Engl J Med. 2018 Sep 13;379(11):e18. doi: 10.1056/NEJMc1808567. N Engl J Med. 2018. PMID: 30211501 No abstract available.
Similar articles
-
First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysis.Clin Lung Cancer. 2019 Sep;20(5):331-338.e4. doi: 10.1016/j.cllc.2019.05.009. Epub 2019 May 11. Clin Lung Cancer. 2019. PMID: 31164319
-
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.Cancer. 2020 Nov 15;126(22):4867-4877. doi: 10.1002/cncr.33142. Epub 2020 Sep 11. Cancer. 2020. PMID: 32914866 Free PMC article.
-
Pembrolizumab plus Chemotherapy in Lung Cancer.N Engl J Med. 2018 Sep 13;379(11):e18. doi: 10.1056/NEJMc1808567. N Engl J Med. 2018. PMID: 30211501 No abstract available.
-
Pembrolizumab plus Chemotherapy in Lung Cancer.N Engl J Med. 2018 Sep 13;379(11):e18. doi: 10.1056/NEJMc1808567. N Engl J Med. 2018. PMID: 30211499 No abstract available.
-
Comparative long-term outcomes of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy as first-line therapy for metastatic non-small-cell lung cancer: a systematic review and network meta-analysis.Front Immunol. 2024 Jul 11;15:1375136. doi: 10.3389/fimmu.2024.1375136. eCollection 2024. Front Immunol. 2024. PMID: 39072325 Free PMC article.
Cited by
-
High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab.Mol Cancer Res. 2021 Sep;19(9):1510-1521. doi: 10.1158/1541-7786.MCR-21-0053. Epub 2021 May 26. Mol Cancer Res. 2021. PMID: 34039647 Free PMC article. Clinical Trial.
-
Phosphorylation of AGO2 by TBK1 Promotes the Formation of Oncogenic miRISC in NSCLC.Adv Sci (Weinh). 2024 Apr;11(15):e2305541. doi: 10.1002/advs.202305541. Epub 2024 Feb 13. Adv Sci (Weinh). 2024. PMID: 38351659 Free PMC article.
-
Live Biotherapeutic Lactococcus lactis GEN3013 Enhances Antitumor Efficacy of Cancer Treatment via Modulation of Cancer Progression and Immune System.Cancers (Basel). 2022 Aug 23;14(17):4083. doi: 10.3390/cancers14174083. Cancers (Basel). 2022. PMID: 36077619 Free PMC article.
-
Novel and emerging therapies for B cell lymphoma.J Hematol Oncol. 2019 Jul 25;12(1):82. doi: 10.1186/s13045-019-0752-3. J Hematol Oncol. 2019. PMID: 31345247 Free PMC article. Review.
-
Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma.Int J Mol Sci. 2021 May 7;22(9):4981. doi: 10.3390/ijms22094981. Int J Mol Sci. 2021. PMID: 34067112 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
